CytomX Therapeutics saw the highest growth of 3.49% in patent filings in May and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.39% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of CytomX Therapeutics‘s patent filings and grants. Buy the databook here.
CytomX Therapeutics has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 36% filings and 50% grants. The United States(US), Israel(IL), Australia(AU), and South Korea(KR) patent Office are among the top ten patent offices where CytomX Therapeutics is filings its patents. Among the top granted patent authorities, CytomX Therapeutics has 50% of its grants in United States(US), 25% in Israel(IL) and 25% in Japan(JP).
Roche and Johnson & Johnson could be the strongest competitors for CytomX Therapeutics
Patents related to rare diseases lead CytomX Therapeutics's portfolio
CytomX Therapeutics has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Breast cancer related patents lead CytomX Therapeutics portfolio followed by liver cancer, and ovarian cancer
CytomX Therapeutics has highest number of patents in breast cancer followed by liver cancer, ovarian cancer, pancreatic cancer, and prostate cancer. For breast cancer, nearly 5% of patents were filed and 4% of patents were granted in Q2 2024.
For comprehensive analysis of CytomX Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.